Pharma USA 2023: What Medicare Reform Means to Patient Access Network Foundation

Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

A Harvard Business School Healthcare Alumni Association Q&A with Louis Kassa, CEO of the Pennsylvania Biotechnology Center.

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.

A Q&A with Dr. Zeynep Ton, professor at the MIT Sloan School of Management.

Mills is working in leadership in two roles, one of which puts her on the forefront of the genomic medicine movement.